Definition of Clinically Distinct Molecular Subtypes in
Estrogen Receptor–Positive Breast Carcinomas Through
Genomic Grade
http://www.biomedcentral.com/1755-8794/2/37
Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6532Sherene Loi, from the Peter MacCallum Cancer Centre, Melbourne, worked with a team of Australian and Belgian researchers to investigate the differences between those estrogen receptor positive (ER+) cancers that respond well to tamoxifen (luminal-A) and those that do not (luminal-B). She said, “This is the first study specifically investigating the biology of the luminal-B, ER+ breast cancer subtype. We propose that activation of GF signaling contributes to this highly proliferative, relatively tamoxifen-insensitive, phenotype and that this exists independently of HER2 overexpression. Targeting this pathway and its upstream mediators could prove to be a useful therapeutic strategy
http://www.sciencedaily.com/releases/2009/06/090623215852.htm
and
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2990
No comments:
Post a Comment